Rentosertib moved protein-based aging clocks in a small IPF analysis

What is newly reported

On September 7, researchers published a secondary analysis of blood samples from a phase 2a idiopathic pulmonary fibrosis trial. They applied six protein-based aging clocks to samples collected before treatment and after 2, 4 and 12 weeks. This is new biomarker reporting from an existing disease-treatment trial—not a new longevity trial.

What researchers did

The parent trial randomized 71 adults across three rentosertib regimens and placebo. The clock paper analyzed the 42 participants who consented and had complete samples at every timepoint: 11, 11, 11 and 9 people in the four groups. Small group sizes matter because every clock, regimen and timepoint creates another comparison.

The six clocks were trained for different purposes and do not represent one agreed biological-age measurement. The authors also compared treatment-associated proteins with age-associated protein patterns in an external cohort. That comparison can generate hypotheses, but it cannot separate fibrosis biology from aging biology.

What they found

Across 54 regimen–time–clock comparisons, 21 met the authors’ false-discovery threshold of Q<0.10. The reported shifts were concentrated at week 4. Some clock outputs then plateaued or moved back toward baseline by week 12, and the pattern varied across clocks and regimens.

The important result is therefore narrower than “the drug made people younger.” Particular statistical outputs changed in a selected, small disease cohort over 12 weeks. No healthspan or lifespan outcome was measured.

The underlying trial does not settle the question

The registered primary outcome of NCT05938920 was safety. Forced vital capacity was a secondary outcome. The parent report described a favorable 12-week mean FVC difference for one regimen, but a short phase 2a secondary result with wide uncertainty is not proof of durable anti-fibrotic benefit—and it does not validate the clock changes as an aging endpoint.

The governing registry is NCT05938920. One bibliography entry in the proteomics paper points to NCT05975983, a different phase 2 study. MoreYears.news used the Results section, parent trial report and registry to preserve the governing identity rather than conflating the two studies.

How strong is the aging claim?

Early and exploratory. The analysis used randomized parent-trial groups, but it was not a prespecified longevity outcome in a population recruited to study aging. Complete-sample selection, small cells, short follow-up, one-sided testing and many comparisons limit the result. The authors themselves state that the clocks cannot disentangle anti-fibrotic effects from effects on aging biology.

A separate August 21 methods analysis of 51 intervention datasets found that aging-biomarker responsiveness changes with the clock, intervention, population and study duration. A responsive clock may be useful for research; responsiveness alone does not make it a validated substitute for clinical outcomes.

What should readers watch next?

Independent replication, larger prespecified analyses, longer follow-up and a demonstrated link between the biomarker changes and meaningful patient outcomes would all strengthen the case. The deposited proteomic data, OMIX008341, may help other researchers test the analysis. None of those next steps would remove the need to distinguish disease effects from general aging biology.